

42200

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re application of:

McCormick & Tuse

Serial No. 09/522,900

Filed: 10 March 2000

For: Self Antigen Vaccines for Treating B Cell Lymphomas  
And Other Cancers



Art Unit: 1643

Examiner:

PATENT

#10

TECH CENTER 1600/2900

NOV 06 2001

RECEIVED

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:


In accordance with 37 C.F.R. § 1.97 and § 1.98, Applicants bring the disclosures attached and listed on completed Forms PTO-1449 to the attention of the Examiner and requests that the references be considered and made of record in the instant application.

Since the instant Information Disclosure Statement is being filed prior to issuance of a first Office Action on the merits, no certification under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(b) is required.

Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the instant application.

Prompt examination on the merits is requested respectfully.

Respectfully submitted,

  
Dean H. Nakamura  
Reg. No. 33,981

Roylance, Abrams, Berdo & Goodman, L.L.P.  
1300 19<sup>th</sup> Street, N.W., Suite 600  
Washington, D.C. 20036  
(202) 659-9076

Dated: 1 November 2001